Lv6
2770 积分 2022-12-16 加入
Evolving roles of MET as a therapeutic target in NSCLC and beyond
5天前
已完结
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
13天前
已完结
Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?
16天前
已完结
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
1个月前
已完结
Fighting Cardiac Fibrosis with CAR T Cells
1个月前
已完结
CAR T therapy beyond cancer: the evolution of a living drug
1个月前
已完结
An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma
1个月前
已完结
In vivo CAR T cell generation to treat cancer and autoimmune disease
1个月前
已完结
In vivo CAR engineering for immunotherapy
1个月前
已完结
Trends in the drug target landscape for autoimmune diseases
3个月前
已完结
皖公网安备34019202002308
